Liggins Institute, The University of Auckland, Auckland, New Zealand.
Liggins Institute, The University of Auckland, Auckland, New Zealand
Arch Dis Child Fetal Neonatal Ed. 2022 Sep;107(5):501-507. doi: 10.1136/archdischild-2021-322757. Epub 2021 Dec 2.
To determine the effect of prophylactic dextrose gel on the infant gut microbiome.
Observational cohort study nested in a randomised trial.
Three maternity hospitals in New Zealand.
Infants at risk of neonatal hypoglycaemia whose parents consented to participation in the hypoglycaemia Prevention in newborns with Oral Dextrose trial (hPOD). Infants were randomised to receive prophylactic dextrose gel or placebo gel, or were not randomised and received no gel (controls). Stool samples were collected on days 1, 7 and 28.
The primary outcome was microbiome beta-diversity at 4 weeks. Secondary outcomes were beta-diversity, alpha-diversity, bacterial DNA concentration, microbial community stability and relative abundance of individual bacterial taxa at each time point.
We analysed 434 stool samples from 165 infants using 16S rRNA gene amplicon sequencing. There were no differences between groups in beta-diversity at 4 weeks (p=0.49). There were also no differences between groups in any other microbiome measures including beta-diversity (p=0.53 at day 7), alpha-diversity (p=0.46 for day 7 and week 4), bacterial DNA concentration (p=0.91), microbial community stability (p=0.52) and microbial relative abundance at genus level. There was no evidence that exposure to any dextrose gel (prophylaxis or treatment) had any effect on the microbiome. Mode of birth, type of milk fed, hospital of birth and ethnicity were all associated with differences in the neonatal microbiome.
Clinicians and consumers can be reassured that dextrose gel used for prophylaxis or treatment of neonatal hypoglycaemia does not alter the neonatal gut microbiome.
12614001263684.
确定预防性葡萄糖凝胶对婴儿肠道微生物组的影响。
随机试验中嵌套的观察性队列研究。
新西兰的三家产科医院。
有新生儿低血糖风险的婴儿，其父母同意参与新生儿口服葡萄糖预防低血糖试验（hPOD）。婴儿被随机分配接受预防性葡萄糖凝胶或安慰剂凝胶，或未随机分配且未接受凝胶（对照组）。在第 1、7 和 28 天收集粪便样本。
主要结局是 4 周时的微生物组β多样性。次要结局是β多样性、α多样性、细菌 DNA 浓度、微生物群落稳定性和每个时间点的单个细菌分类群的相对丰度。
我们使用 16S rRNA 基因扩增子测序分析了 165 名婴儿的 434 个粪便样本。4 周时，各组之间的β多样性无差异（p=0.49）。在任何其他微生物组测量中，包括β多样性（第 7 天为 p=0.53）、α多样性（第 7 天和第 4 周为 p=0.46）、细菌 DNA 浓度（p=0.91）、微生物群落稳定性（p=0.52）和属水平的微生物相对丰度，各组之间也没有差异。没有证据表明接触任何葡萄糖凝胶（预防或治疗）对微生物组有任何影响。分娩方式、喂养的奶类型、分娩医院和种族均与新生儿微生物组的差异相关。
临床医生和消费者可以放心，用于预防或治疗新生儿低血糖的葡萄糖凝胶不会改变新生儿肠道微生物组。
12614001263684。
